Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, has been reported to show an improvement in lung function in patients with chronic obstructive pulmonary disease in four Phase 3 trials published in The Lancet. The drug is produced by Nycomed.
Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, has been reported to show an improvement in lung function in patients with chronic obstructive pulmonary disease in four Phase 3 trials published in The Lancet. The drug is produced by Nycomed.